amino acid sequence raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-09-01 and is reviewed periodically as new material appears.
Published clinical evidence is limited. Most controlled trials were conducted in Russia, enrolled modest numbers of participants, and appeared in Russian-language journals, which restricts independent verification. Reported outcomes include lower anxiety scores, improved attention and memory measures, and changes in fatigue ratings. Reviews written in English note methodological limitations such as small samples and inconsistent endpoints. Whether the compound produces clinically meaningful benefit relative to established anxiolytics is therefore an open question rather than an established finding.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a structural analogue of tuftsin, a naturally occurring tetrapeptide fragment of the immunoglobulin heavy chain. The added Pro-Gly-Pro tail was intended to slow enzymatic degradation and extend biological activity. In Russia it is registered as an anxiolytic nasal preparation, while regulators elsewhere have not approved it for clinical use.
Proposed mechanisms centre on modulation of the GABAergic system, with reports of altered expression of genes related to GABA-A receptor subunits and changed monoamine turnover. Some studies describe inhibition of enkephalinase, the enzyme that degrades endogenous enkephalins, which may prolong opioid peptide signalling. Effects on brain-derived neurotrophic factor and on cytokine expression have also been reported. These findings come largely from animal models and small human studies, and the precise primary target remains unresolved.
Reversed-phase high-performance liquid chromatography is the standard technique for estimating peptide purity. The result is a peak-area percentage, which describes how much of the detected material elutes as the main peak in one run. Mass spectrometry confirms the molecular mass and can reveal truncated, adducted, or otherwise modified species. Amino acid analysis or tandem mass spectrometry can address sequence fidelity when identity is in doubt. None of these measurements, taken alone, establishes that a sample is fit for any specific purpose.
Lyophilized selank is normally supplied as a dry powder and is considered stable for extended periods when kept cold and dry. Moisture uptake is the main practical threat, because absorbed water promotes both hydrolysis and aggregation in the solid state. Vials are usually warmed to room temperature before opening so that condensation does not form on the powder. Supplier documentation commonly specifies -20 °C for routine storage, with -80 °C used for material intended to be archived for years.
Once dissolved, the peptide is markedly less stable than the dry powder. Aqueous solutions are subject to backbone hydrolysis and to microbial growth when they are handled without sterile technique. Buffered solutions near neutral pH are common for short-term laboratory work, while acidic conditions are sometimes used to improve solubility. Analytical laboratories generally prepare working solutions fresh rather than storing them, and a residual water film left in a reopened vial can seed degradation even when the container appears dry.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C33H57N11O9 | Free peptide form |
| Molecular mass | About 751.9 Da | Calculated average mass |
| Amino acid sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Single-letter form TKPRPGP |
| Structural basis | Tuftsin analogue | Extended version of a natural tetrapeptide |
| Development origin | Russian Academy of Sciences | Work carried out from the 1980s onward |
Regulatory treatment varies by jurisdiction. In Russia the compound is a registered prescription product, while in the European Union and the United States it is generally handled as a research chemical without a marketing authorization. Suppliers therefore operate outside pharmaceutical oversight, and buyers rely on supplier documentation for purity and identity claims. Chain of custody and third-party testing are the main verification tools. Analysts note that the absence of a pharmacopoeial monograph for research-grade material limits standardization across vendors.
Purity assessment relies mainly on reverse-phase high-performance liquid chromatography with ultraviolet detection. Because the peptide lacks a strong chromophore, detection often uses backbone absorbance near 214 nm. Identity is confirmed by mass spectrometry, typically electrospray ionization or matrix-assisted laser desorption, comparing the measured mass against the expected value. Amino acid analysis can verify composition after acid hydrolysis. Diastereomer content and residual counterions are reported less often, although both can influence biological assays.
Lyophilized material is generally stable for extended periods when kept dry at or below minus twenty degrees Celsius. Working solutions are less stable, and common practice is to aliquot and freeze them so that repeated freeze-thaw cycles are avoided. Aqueous solutions are sensitive to pH extremes and to microbial growth, so short-term storage at refrigerator temperature is typical. Oxidation and hydrolysis are the principal degradation routes. Reconstitution with sterile water or a mild buffer is standard, and solutions should be protected from light.
Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.
Outside its country of origin the compound is generally handled as a research chemical rather than an approved medicine. No regulatory approval from the United States Food and Drug Administration or the European Medicines Agency has been granted for human use. Identity and purity are normally checked by reverse-phase high-performance liquid chromatography, with mass spectrometry used to confirm the molecular mass. Lyophilised material is stored cold and desiccated, and repeated freeze-thaw cycles are avoided.
Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, with mass spectrometry used to confirm molecular mass and sequence information. Amino acid analysis and peptide mapping may supplement these methods. Certified reference standards are scarce, and many commercial lots are sold as research chemicals without a pharmacopoeial monograph. Regulatory treatment differs by country: Selank is a registered prescription medicine in Russia, while in the European Union and the United States it is not an approved drug and may fall under research-chemical or unapproved-product frameworks.
Selank is a hydrophilic peptide and dissolves readily in water and in aqueous buffers. The lyophilised powder is typically a white to off-white solid. Because short peptides are prone to hydrolysis and oxidation, handling benefits from limiting exposure to heat, moisture and strong light. Working solutions are commonly prepared in sterile water or saline, and repeated freeze-thaw cycles are avoided to reduce aggregation and loss of activity. These practices reflect general laboratory convention rather than published stability specifications.
The primary structure of Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, corresponding to the molecular formula C33H57N11O9 and a monoisotopic mass of roughly 751.9 daltons. The N-terminal threonine and the arginine residue in the fourth position are shared with tuftsin, which carries the sequence Thr-Lys-Pro-Arg. The three additional residues at the C-terminus, Pro-Gly-Pro, extend the chain and are associated with greater resistance to enzymatic degradation. This extension also separates Selank from the shorter parent peptide.
Naming conventions place Selank in the same research family as Semax, another Russian-developed peptide investigated for cognitive effects. The two compounds share a lineage but differ in sequence and in the biological systems proposed as their targets. Semax descends from ACTH fragments, whereas Selank descends from tuftsin. Publications sometimes identify Selank by its full peptide sequence or by laboratory codes rather than one uniform trade name. Because replication outside Russia is limited, reports on its properties are best read alongside the study design and the purity of the material tested.
The first mountain-building tectonic plate collision that initiated the construction of what are today the Appalachians occurred at least a billion years ago when the pre-North American craton called Laurentia collided with at least one other craton — Amazonia. All the other cratons of the earth also collided at about this time to form the supercontinent Rodinia and were surrounded by one single ocean. (It is possible that the cratons of Kalahari, and Rio Plato, were also part of that early collision since they were present as Rodinia broke up). Mountain-building referred to as the Grenville Orogeny occurred along the boundaries of the cratons. The present Appalachian Mountains have at least two areas which are made from rock formations that were formed during this orogeny - the Blue Ridge Mountains and the Adirondacks.
== Good country == The Good Country Index seeks to measure every country's "contribution to the common good of humanity and the planet". Of 153 nations ranked in 2018, Thailand ranked 60 (1=best; 153=worst). Other ASEAN nations were ranked: Singapore, 23; Malaysia, 45; Philippines, 69; Brunei, 70; Indonesia, 87; Vietnam, 116; Cambodia, 130; Laos, 134. Myanmar was not included due to lack of data.
Although flightless, emus have vestigial wings, the wing chord measuring around 20 cm (8 in), and each wing having a small claw at the tip. Emus flap their wings when running, perhaps as a means of stabilising themselves when moving fast. They have long necks and legs, and can run at speeds of 48 km/h (30 mph) due to their highly specialised pelvic limb musculature. Their feet have only three toes and a similarly reduced number of bones and associated foot muscles; emus are unique among birds in that their gastrocnemius muscles in the back of the lower legs have four bellies instead of the usual three. The pelvic limb muscles of emus contribute a similar proportion of the total body mass as do the flight muscles of flying birds. When walking, the emu takes strides of about 100 cm (3.3 ft), but at full gallop, a stride can be as long as 275 cm (9 ft). Its legs are devoid of feathers and underneath its feet are thick, cushioned pads. Like the cassowary, the emu has sharp claws on its toes which are its major defensive attribute, and are used in combat to inflict wounds on opponents by kicking. The toe and claw total 15 cm (6 in) in length. The bill is quite small, measuring 5.6 to 6.7 cm (2.2 to 2.6 in), and is soft, being adapted for grazing. Emus have good eyesight and hearing, which allows them to detect threats at some distance.
=== Range === DASH7 provides a link budget of up to 140 dB with 27 dBm transmission power, which positions the technology as medium-range, compared to short-range (Bluetooth, Wi-Fi, ...) and long-range (LoRaWAN, SigFox). Note that higher ranges are always obtained at the expense of per-bit power consumption and transmission duration. Low-power long-range technologies are generally not truly bi-directional, as the regular scanning duty is pretty high. In this context, DASH7 is a very good compromise between range, power consumption, and bi-directionality and is very suitable for industrial applications with effective range of 100 to 500 m. In line-of-sight situations, DASH7 devices today advertise read ranges of 1 kilometer or more, however, ranges of up to 10 km have been tested by Savi Technology and are easily achievable in the European Union, where governmental regulations are less constrained than in the USA.
Organized crime refers to groups of centralized enterprises that engage in, and aim to profit from, illegal activities. Some forms of organized crime exist simply to meet demand for illegal goods or to facilitate trade in products and services banned by the state, such as illegal drugs or firearms. In other cases, criminal organizations force people to do business with them, as when gangs extort protection money from shopkeepers. In the United States, the Organized Crime Control Act (1970) defines organized crime as "[t]he unlawful activities of [...] a highly organized, disciplined association [...]". Criminal activity as a structured process is referred to as racketeering. In the UK, police estimate that organized crime involves up to 38,000 people operating in 6,000 various groups. Historically, the largest organized crime force in the United States has been Cosa Nostra (Italian-American Mafia), but other transnational criminal organizations have also risen in prominence in recent decades. A 2012 article in a U.S. Department of Justice journal stated that: "Since the end of the Cold War, organized crime groups from Russia, China, Italy, Nigeria, and Japan have increased their international presence and worldwide networks or have become involved in more transnational criminal activities.
Sources: en.wikipedia.org
== Role of the clinical data manager in a clinical trial == Job profile acceptable in CDM: clinical researcher, clinical research associate, clinical research coordinator etc. The clinical data manager plays a key role in the setup and conduct of a clinical trial. The data collected during a clinical trial form the basis of subsequent safety and efficacy analysis which in turn drive decision making on product development in the pharmaceutical industry. The clinical data manager is involved in early discussions about data collection options and then oversees development of data collection tools based on the clinical trial protocol. Once subject enrollment begins, the data manager ensures that data are collected, validated, complete, and consistent. The clinical data manager liaises with other data providers (e.g. a central laboratory processing blood samples collected) and ensures that such data are transmitted securely and are consistent with other data collected in the clinical trial. At the completion of the clinical trial, the clinical data manager ensures that all data expected to be captured have been accounted for and that all data management activities are complete. At this stage, the data are declared final (terminology varies, but common descriptions are "Database Lock", “Data Lock” and "Database Freeze"), and the clinical data manager transfers data for statistical analysis.
If a designer is interested only in the best sequence, the protein design algorithm only requires the lowest-energy conformation of the lowest-energy sequence. In these cases, the amino acid identity of each rotamer can be ignored and all rotamers belonging to different amino acids can be treated the same. Let ri be a rotamer at residue position i in the protein chain, and E(ri) the potential energy between the internal atoms of the rotamer. Let E(ri, rj) be the potential energy between ri and rotamer rj at residue position j. Then, we define the optimization problem as one of finding the conformation of minimum energy (ET):
=== Depression === In the United States, citalopram is approved to treat major depressive disorder. Citalopram appears to have comparable efficacy and superior tolerability relative to other antidepressants. In the National Institute for Health and Clinical Excellence ranking of ten antidepressants for efficacy and cost-effectiveness, citalopram is fifth in effectiveness (after mirtazapine, escitalopram, venlafaxine, and sertraline) and fourth in cost-effectiveness. Evidence for the effectiveness of citalopram for treating depression in children is uncertain.
In response to sustained high levels of migration and growing political pressure, the administration implemented stricter measures beginning in 2023. Biden faced criticism from immigration advocates for extending Title 42, a Trump administration border restriction that arose due to the COVID-19 pandemic, and for restarting the use of "expedited removal" of certain Central American families. In May 2023, the Biden administration approved sending 1,500 more troops to the U.S.-Mexico border as Title 42 expired. In January 2024, Biden expressed support for a proposed bipartisan immigration deal led by Senators Kyrsten Sinema and James Lankford. The proposed bipartisan bill would have allowed Department of Homeland Security (DHS) to close the border when encounters reach a seven-day average of 5,000 or exceed 8,500 in a single day. In addition, the bill would have mandated the detention of migrants seeking asylum and undergoing asylum interviews, with those failing the process repatriated to their home countries. While not addressing the status of "Dreamers", it would have changed immigration law to allow the children of those with H-1B visas to get work authorizations and freeze their legal ages while waiting for green cards, rather than face deportation once they turn 21, and provide additional funding for immigration judges. Former president Donald Trump announced his opposition to the legislation, calling on Congressional Republicans to oppose it; subsequently, leaders such as Speaker of the House Mike Johnson announced their opposition, halting further legislative action.
Withdrawal effects may also occur when switching a person from one antipsychotic to another, (it is presumed due to variations of potency and receptor activity). Such withdrawal effects can include cholinergic rebound, an activation syndrome, and motor syndromes including dyskinesias. These adverse effects are more likely during rapid changes between antipsychotic agents, so making a gradual change between antipsychotics minimises these withdrawal effects. The British National Formulary recommends a gradual dose reduction when discontinuing antipsychotic treatment to avoid acute withdrawal symptoms or rapid relapse. The process of cross-titration involves gradually increasing the dose of the new medication while gradually decreasing the dose of the old medication.
Sources: en.wikipedia.org
It is a seven-amino-acid peptide, Thr-Lys-Pro-Arg-Pro-Gly-Pro, produced by chemical synthesis rather than extracted from biological tissue. Its design is based on tuftsin, a natural immunomodulatory tetrapeptide. The C-terminal Pro-Gly-Pro segment is a common stabilising motif in short regulatory peptides.
The core four residues correspond to tuftsin, which occurs naturally as part of immunoglobulin G. The full seven-residue sequence, however, is not a known endogenous peptide. It is a laboratory-designed analogue intended to combine tuftsin-like activity with greater resistance to breakdown.
No single receptor has been confirmed as the primary target. Reports describe involvement of the GABAergic system, interference with enkephalin degradation, and shifts in neurotrophic factor expression. Because these observations come from different models and assays, they have not yet been integrated into one accepted mechanism.
Sealed, desiccated storage at -20 °C or colder is the standard recommendation for research-grade material. Vials should reach room temperature before they are opened, which limits condensation. Repeated temperature cycling is discouraged.